Neonatal drug trials: impact of EU and US paediatric regulations
- 3 May 2014
- journal article
- postscript
- Published by BMJ in Archives of Disease in Childhood: Fetal & Neonatal
- Vol. 99 (5), F438
- https://doi.org/10.1136/archdischild-2013-305900
Abstract
The rational use of medicines in neonates is limited by the lack of scientific evidence for their use, as most medicines used in neonates are either unlicensed or off-label.1 In order to improve this situation, legislation has been passed in Europe and the USA to encourage the pharmaceutical industry to study medicines in the paediatric and neonatal populations. In order to evaluate the impact of these paediatric regulations in the neonatal population, we analysed the drug trials registered in the Clinicaltrials.gov database. Among all (138 948) trials registered, 30 912 (22%) were paediatric trials, and only 288 (0.2%) involved neonates. The number of trials registered grew steadily over time. From 1999 to 2012 trials …Keywords
This publication has 4 references indexed in Scilit:
- The Pediatric Studies Initiative: After 15 Years Have We Reached the Limits of the Law?Clinical Therapeutics, 2014
- Federal Legislation and the Advancement of Neonatal Drug StudiesThe Journal of Pediatrics, 2013
- Pediatric Versus Adult Drug Trials for Conditions With High Pediatric Disease BurdenPediatrics, 2012
- Stimulation programs for pediatric drug research – do children really benefit?European Journal of Pediatrics, 2007